Pen Needles Market To Reach $9.9 Billion By 2033 | CAGR 9.4%

Pen Needles Market Growth & Trends

The global pen needles market size is expected to reach USD 9.9 billion by 2033, registering a CAGR of 9.4% from 2026 to 2033, according to a new report by Grand View Research, Inc. Rising prevalence of diabetes is the primary reason for the significant growth of the pen needles market. According to the National Library of Medicine, the number of people with diabetes is expected to climb by 1.51 million in 2023, owing primarily to the ageing population. Such high prevalence of diabetes across the globe has led to rising demand for pen needles. Patients suffering from diabetes commonly use injectable pen devices, which help in easy drug delivery. 

In addition, obesity is a significant cause of diabetes. Obese people often suffer from type 2 diabetes, which makes them one of the highest revenue contributors to the target market. Thus, people with type 2 diabetes are the common target population for companies manufacturing pen needles. 

Rising technological advancements is also expected to drive the market growth. Pen needles allow comfort and easy mode of insulin delivery. These devices are technologically advanced and provide a superior alternative drug delivery method in comparison to syringes and vials. For instance, Becton, Dickinson, and Company launched BD Ultra-Fine Nano 4mm Pen Needles with Easy Flow Technology, which will enable diabetic patients with easy adherence to insulin therapy regimens.

 Request a free sample copy or view report summary: Pen Needles Market Report

Pen Needles Market Report Highlights

• The standard pen needles segment dominated the market and accounted for the largest share of 87.0% in 2025. The growth is owing to its extensive usage among insulin-dependent diabetic patients and the strong preference for affordable, convenient, and easy-to-use injection devices.

• The 4mm segment is expected to witness the fastest CAGR over the forecast period, owing to the increasing preference for ultra-short needle lengths that enhance patient comfort, reduce injection pain, and improve adherence to insulin therapy.

• The insulin segment dominated the pen needles market in 2025 and expected to witness fastest CAGR over the forecast period, driven by the rising global prevalence of diabetes and the growing dependence on insulin therapy for effective blood glucose management.

• The European pen needles market accounted for the largest share of 36.4% in 2025. The growth is being reshaped by high prevalence of diabetes, increasing adoption of self-injection devices, and strong healthcare infrastructure.

Pen Needles Market Segmentation

Grand View Research has segmented the global pen needles market based on product, needle length, therapy, and region:

Pen Needles Product Outlook (Revenue, USD Billion, 2021 - 2033)

• Standard Pen Needles

• Safety Pen Needles

Pen Needles Needle Length Outlook (Revenue, USD Billion, 2021 - 2033)

• 4mm

• 5mm

• 6mm

• 8mm

• 10mm

• 12mm

Pen Needles Therapy Outlook (Revenue, USD Billion, 2021 - 2033)

• Insulin

• Glucagon-like-peptide-1

• Growth Hormone

Pen Needles Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • China

  • Japan

  • South Korea

  • Thailand

  • Australia

  • India

• Latin America

  • Brazil

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Pen Needles Market

• Novo Nordisk A/S

• Becton Dickinson and Company

• Terumo Corp.

• Owen Mumford Ltd.

• Ypsomed

• B. Braun Melsungen AG

• HTL-STREFA

• UltiMed, Inc.

• Allison Medical, Inc.

• Artsana S.p.A.